MY163074A - Formulations comprising methylthioninium chloride - Google Patents

Formulations comprising methylthioninium chloride

Info

Publication number
MY163074A
MY163074A MYPI2013001934A MYPI2013001934A MY163074A MY 163074 A MY163074 A MY 163074A MY PI2013001934 A MYPI2013001934 A MY PI2013001934A MY PI2013001934 A MYPI2013001934 A MY PI2013001934A MY 163074 A MY163074 A MY 163074A
Authority
MY
Malaysia
Prior art keywords
formulations
methylthioninium chloride
dosage forms
mtc
solid dosage
Prior art date
Application number
MYPI2013001934A
Other languages
English (en)
Inventor
Karrar Ahmad Khan
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MY163074A publication Critical patent/MY163074A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2013001934A 2010-11-30 2011-11-30 Formulations comprising methylthioninium chloride MY163074A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41816410P 2010-11-30 2010-11-30

Publications (1)

Publication Number Publication Date
MY163074A true MY163074A (en) 2017-08-15

Family

ID=45418703

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013001934A MY163074A (en) 2010-11-30 2011-11-30 Formulations comprising methylthioninium chloride

Country Status (10)

Country Link
US (1) US9192611B2 (https=)
EP (1) EP2645994B1 (https=)
JP (1) JP6093707B2 (https=)
CN (1) CN103379901B (https=)
AU (1) AU2011334679B2 (https=)
CA (1) CA2818068C (https=)
ES (1) ES2655492T3 (https=)
MY (1) MY163074A (https=)
SG (2) SG190406A1 (https=)
WO (1) WO2012072977A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014153444A (ja) * 2013-02-06 2014-08-25 Konica Minolta Inc 位相差フィルム、偏光板及び液晶表示装置
KR102592614B1 (ko) 2016-07-25 2023-10-24 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
FR3104438B1 (fr) 2019-12-12 2021-11-19 Univ Bordeaux Formulation pour le bleu de methylene et procede
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
AU2023346900A1 (en) 2022-09-21 2025-04-10 TauRx Therapeutics Management Ltd Novel formulations and vehicles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
JPH0840942A (ja) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 薬物放出制御製剤
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
AU2005286235C1 (en) 2004-09-23 2013-08-22 TauRx Therapeutics Management Ltd Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC)
ATE415148T1 (de) * 2004-10-19 2008-12-15 Krka Tovarna Zdravil D D Novo Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
DE602006006536D1 (de) * 2006-01-05 2009-06-10 Teva Pharma Trockene Aripiprazolformulierungen
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
CA3027974C (en) 2007-10-03 2022-03-15 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
PL2480540T3 (pl) * 2009-09-24 2018-05-30 Wista Laboratories Ltd. Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne

Also Published As

Publication number Publication date
CA2818068C (en) 2019-06-11
WO2012072977A3 (en) 2012-08-16
WO2012072977A8 (en) 2012-09-20
CN103379901A (zh) 2013-10-30
SG190406A1 (en) 2013-06-28
JP6093707B2 (ja) 2017-03-08
JP2013544272A (ja) 2013-12-12
AU2011334679A1 (en) 2013-07-18
CA2818068A1 (en) 2012-06-07
AU2011334679B2 (en) 2016-12-15
SG10201602111VA (en) 2016-04-28
US9192611B2 (en) 2015-11-24
US20130243858A1 (en) 2013-09-19
ES2655492T3 (es) 2018-02-20
CN103379901B (zh) 2018-04-03
WO2012072977A2 (en) 2012-06-07
EP2645994A2 (en) 2013-10-09
EP2645994B1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
ZA201500316B (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX348823B (es) Formulaciones estables de linaclotida.
GB2492305A (en) Polymers of benzodithiophene and their use as organic semiconductors
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
SG195086A1 (en) Compounds containing hydrido-tricyano-borate anions
PL2550018T3 (pl) Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
EP2832745A4 (en) HIGH-PURITY CYCLOPEPTIDE COMPOUND AND PROCESS FOR THE PREPARATION AND USE THEREOF
PH12018502580A1 (en) Formulations for paddy rice fields
ZA201209539B (en) Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
SG10201706643XA (en) Formulations and methods for nutrient delivery
IN2014KN00892A (https=)
IN2012DN03404A (https=)
MY163074A (en) Formulations comprising methylthioninium chloride
IN2014KN00893A (https=)
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
SI2871941T1 (sl) Sestave in metode za zmanjšanje reproduktivne zmogljivosti podganjih samic
ZA201209395B (en) Trisaccharide derivates,and their use as adjuvants
UA92872C2 (ru) Комбинированное антиагрегантное и антиоксидантное лекарственное средство
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
UA58018U (ru) Применение хондроитина сульфата для коррекции нарушений сперматогенеза у крыс
UA34455U (ru) Применение эпиталона как препарата для коррекции изменений про- и антиоксидантной защиты при стрессе в эксперименте
UA51902U (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) в качестве способа фригопротекторного действия